Skip to search formSkip to main contentSkip to account menu

Phosphodiesterase 4 Inhibitors

Known as: PDE 4 Inhibitors, Inhibitors, Phosphodiesterase 4, Phosphodiesterase Type 4 Inhibitors 
Compounds that specifically inhibit PHOSPHODIESTERASE 4.
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (6)

CilomilastKW 4490MK 0873Rolipram
In BloodPhosphodiesterase 4 Inhibitor [EPC]aspects of radiation effectschemical synthesis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4
This study examined the role of the main vascular cAMP‐hydrolysing phosphodiesterases (cAMP‐PDE) in the regulation of basal… 
2012
2012
NADPH oxidase 4 mediates upregulation of type 4 phosphodiesterases in human endothelial cells
The protective actions of prostacyclin (PGI2) are mediated by cyclic AMP (cAMP) which is reduced by type 4 phosphodiesterases… 
2009
2009
Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (−)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium
Acting through a low-affinity site of the β1-adrenoceptor (β1LAR), CGP12177 causes sinoatrial tachycardia and positive inotropic… 
2008
2008
A Cell-Based PDE4 Assay in 1536-Well Plate Format for High-Throughput Screening
The cyclic nucleotide phosphodiesterases (PDEs) are intracellular enzymes that catalyze the hydrolysis of 3,′5′-cyclic… 
2006
2006
cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling.
Specificity of cAMP signalling pathways has shown that the intracellular targeting of the individual components confers a three… 
Review
2005
Review
2005
Inhibitors of PDE4: a review of recent patent literature
The preregistration of roflumilast and the preapproval by the US Food and Drug Administration of cilomilast highlight the… 
2005
2005
Practical asymmetric synthesis of a potent PDE4 inhibitor via stereoselective enolate alkylation of a chiral aryl-heteroaryl secondary tosylate.
A practical, chromatography-free catalytic asymmetric synthesis of a potent and selective PDE4 inhibitor (L-869,298, 1) is… 
Highly Cited
2003
Highly Cited
2003
Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel…
A SAR study on the tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors related to 1 is described. In addition to… 
Review
2000
Review
2000
The potential of PDE4 inhibitors in asthma or COPD.
At least 11 families of distinct phosphodiesterase (PDE) isoenzymes are known to regulate the function of many cells secondary to… 
Review
2000
Review
2000
New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease.
Phosphodiesterase 4 (PDE4) is a member of the growing family cyclic AMP and cyclic GMP. Earliest described inhibitors of PDE4… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)